MedicaidPrior AuthMedium impact
Imjudo (tremelimumab-actl) (New)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Louisiana Medicaid has established a new prior authorization policy for Imjudo (tremelimumab-actl), a cancer immunotherapy drug used to treat unresectable hepatocellular carcinoma and metastatic non-small cell lung cancer. Prior authorization will be required for all Imjudo treatments, with specific criteria including combination therapy requirements and genomic testing results.
Action Required
Before December 1, 2025: Billing team must implement prior authorization requirements for Imjudo (tremelimumab-actl) treatments for Louisiana Medicaid patients. Update billing system to flag cases requiring prior auth for hepatocellular carcinoma and non-small cell lung cancer treatments. Providers must document unresectable diagnosis, combination therapy plans with Imfinzi, and genomic testing results where applicable. Claims without prior authorization will be denied.